Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hay Fever: later-stage trial registry
A small indexed set (4 trials) with no open enrollment listed right now.
Corpus placement: #4,115 of 28,707 conditions by registered trial count.
4 US clinical trials · none currently recruiting · #4,115 of 28,707 conditions by registered trial count
Hay Fever: 4 US clinical trials tracked, none currently recruiting.
Hay Fever is the subject of 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting. 2 are in Phase 3-4 (later-stage) and 1 in Phase 1-2 (earlier-stage). The most active sponsor is AstraZeneca, running 2 of these trials.
Enrollment posture brief
Registry condition hay-fever
OPEN 0 | RECR 0% | LATE 2 | EARLY 1 | RANK #4115 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Accelerated Phase Chronic Myelogenous Leukemia (0% recruiting · 12 trials)
Hay Fever has no open enrollment in this registry pull (4 archived studies). Peers show how other volume-matched labels compare on open share. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hay Fever on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hay Fever is recruiting below its size-band peers.
0 of 4 indexed trials (0%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
Indexed trials (enrollment closed)
4 total, page 1 of 1
Safety and Efficacy of Ciclesonide in Pediatric Patients (6 to 11 Years of Age) With Seasonal Allergic Rhinitis (BY9010/M1-417)
AstraZeneca
NCT00305487
Audio Data Collection for Identification and Classification of Coughing
HealthMode
NCT04326309
To Assess the Safety and Efficacy of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-401)
AstraZeneca
NCT00659841
Omalizumab (Xolair) and Allergy Shots For the Treatment of Seasonal Allergies
National Institute of Allergy and Infectious Diseases (NIAID)
NCT00078195
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 1 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Hay Fever records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hay Fever trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hay Fever page
4 registered trials, 0 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- No Hay Fever trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- AstraZeneca sponsors the most Hay Fever trials on record, review their full trial history before evaluating a specific study. See AstraZeneca's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hay Fever condition card totals 4 registered trials; most-linked intervention Ciclesonide nasal spray; top US site state Wisconsin. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.